Innate Pharma announced that it has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.
Innate Pharma is a clinical-stage biotechnology company based in Marseille, France, which specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body’s immune system to recognize and kill cancer cells.
The Phase I/II study will evaluate the safety and efficacy of durvalumab, an anti-PD-L1 immune checkpoint inhibitor, in combination with Innate’s investigational first-in-class anti-C5aR monoclonal antibody, IPH5401, as a treatment for patients with selected solid tumors.
“Our collaboration with MedImmune provides further evidence of Innate’s commitment to exploring the full combination potential of IPH5401 as we progress our immuno-oncology portfolio,” said Mondher Mahjoubi, Chief Executive Officer of Innate Pharma. “We believe IPH5401 could become an important partner in PD-1/PD-L1 combination strategies.”
The Phase I part of the trial is expected to establish a recommended dose regimen of IPH5401 in combination with durvalumab in selected solid tumors, and the Phase II part will assess the safety and efficacy of the combination in these patients.
As part of a broad development programme, durvalumab is being investigated as monotherapy and in combination with IO, small molecules, and chemotherapies across a range of tumours and stages of disease.